Nuvalent, Inc. (NUVL) Stock
7 of the hedge funds AlphaScala tracks reported NUVL in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $49.92M.
Which hedge funds own NUVL?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 404K | $49.92M | +2138% |
| Soros Fund Management George Soros (founder) | 300K | $37.05M | NEW |
| Renaissance Technologies Jim Simons (founder) | 281K | $34.69M | +216% |
| Marshall Wace | 152K | $18.79M | +4663% |
| Point72 Steve Cohen | 46K | $5.72M | NEW |
| Citadel Ken Griffin | 44K | $5.43M | -74% |
| D.E. Shaw David Shaw | 7K | $816.7K | NEW |
13F holdings as of Jun 30, 2026
Explore all tracked funds →NUVL price chart
Powered by TradingViewWhat does Nuvalent, Inc. do?
Nuvalent Inc. is a biopharmaceutical company dedicated to the innovative development of small molecule therapies for cancer treatment. The company's primary focus is on creating targeted solutions for patients with cancer-related resistance mutations and treatment-related adverse effects. By leveraging their expertise in medicinal chemistry and deep understanding of tumor biology, Nuvalent aims to address significant gaps in current cancer therapies, particularly where existing treatments fall short due to resistance mechanisms. The company operates in a highly specialized sector that covers oncology research and development, presenting potential game-changing approaches within the broader pharmaceutical industry. Through its commitment to research and innovation, Nuvalent collaborates with leading research institutions to push the boundaries of what is achievable in cancer treatment. Situated within an ever-evolving market, the company plays a critical role in advancing new oncological solutions that may ultimately improve the quality of life for patients globally. Founded with the mission to transform patient care, Nuvalent's asset offerings are a testament to the progressive strides being made in next-generation cancer therapeutics.